CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

@article{Masuda1992CPT11AN,
  title={CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.},
  author={Norikazu Masuda and Masahiro Fukuoka and Yasuo Kusunoki and Kaoru Matsui and Nobuhide Takifuji and Shinzoh Kudoh and Shunichi Negoro and Masayuki Nishioka and Kazuhiko Nakagawa and Minoru Takada},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1992},
  volume={10 8},
  pages={
          1225-9
        }
}
PURPOSE To evaluate the activity of CPT-11, which is a new derivative of camptothecin, against refractory or relapsed small-cell lung cancer (SCLC). PATIENTS AND METHODS Sixteen patients with refractory or relapsed SCLC were entered onto a prospective, non-randomized, single-institution phase II trial. All 16 patients had been pretreated heavily with some form of cisplatin-based combination chemotherapy. Five patients had received previous chemotherapy with cisplatin, vincristine, doxorubicin… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 138 CITATIONS

FILTER CITATIONS BY YEAR

1993
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 7 Citations per year over the last 3 years

Similar Papers

Loading similar papers…